GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Short Interest

Moderna (LTS:0A45) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Moderna Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Moderna's Short Interest

For the Biotechnology subindustry, Moderna's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Short Interest distribution charts can be found below:

* The bar in red indicates where Moderna's Short Interest falls into.


Moderna (LTS:0A45) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Short Interest
Comparable Companies
BNTX BGNE ALNY SGEN BMRN RPRX LEGN INCY UTHR SRPT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB XKRX:068270
Traded in Other Exchanges
MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria
Address
200 Technology Square, Cambridge, MA, USA, 02139
Website
https://www.modernatx.com
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines